Related Experiment Video
Updated: Sep 11, 2025
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
In the wake of the Scandinavian Simvastatin Survival Study trial
1Department of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki.
Insights
Statins, like simvastatin, significantly reduce cardiovascular events and mortality. Long-term use and accessibility are key to maximizing the benefits of cholesterol-lowering therapy for atherosclerotic vascular disease prevention.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Public Health
Background:
- The 4S trial revolutionized cardiovascular disease treatment by demonstrating simvastatin's efficacy in reducing atherosclerotic vascular disease (ASCVD) events and all-cause mortality.
- Over 30 years, statins have become well-tolerated, effective therapies, driving innovation in dyslipidemia management.
Purpose of the Study:
- To review current knowledge on statins, focusing on vascular and nonvascular benefits, adverse effects, and adherence.
- To discuss the evolving treatment paradigms for cholesterol lowering, emphasizing long-term LDL reduction for ASCVD prevention.
Main Methods:
- Literature review of studies following the 4S trial.
- Analysis of data on statin efficacy, safety, and patient adherence.
Main Results:
- Statins offer significant vascular and nonvascular benefits, with a trend towards 'the lower the better' for LDL cholesterol.
- Long-term statin therapy is increasingly recognized for its potential to reduce lifetime LDL burden and enhance ASCVD prevention.
- New treatments are being developed to complement statins in managing atherosclerotic lipoproteins and residual risk.
Conclusions:
- Generic statins are affordable, well-tolerated, and can substantially reduce the global burden of atherosclerotic vascular disease.
- Improving accessibility and adherence to statin therapy are crucial for realizing their full public health potential.
Purpose Of Review:
In 1994, the 4S trial was revolutionary by showing that cholesterol lowering with simvastatin reduced, not only atherosclerotic vascular disease (ASCVD) events, but also all-cause mortality as compared to placebo. During the following 30 years, statins have proved to be well tolerated and effective and also paved way for new innovations in the field of dyslipidaemia therapy.
Recent Findings:
The aim of this review is to summarize current knowledge about statins and effects of cholesterol-lowering accumulated in the wake of 4S trial: both vascular and nonvascular benefits, adverse effects, adherence, and statin intolerance. While secondary prevention of ASCVD has emphasized 'the lower the better' in LDL-cholesterol lowering, emerging topic is 'the longer the better' to reduce lifetime LDL burden and achieve full potential of ASCVD prevention. With statins as backbone therapy, new treatment innovations are in trials to better manage all atherosclerotic lipoproteins and residual risk.
Summary:
After becoming generic, statins are inexpensive and well tolerated therapy with potential to substantially reduce the burden of atherosclerotic vascular disease world-wide. To achieve these goals, both accessibility and adherence are fundamental issues.
Related Concept Videos
01:21Cancer Survival Analysis
01:15Assumptions of Survival Analysis
01:20Comparing the Survival Analysis of Two or More Groups
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:20Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...